Compositions of β-glucans and specific antibodies

Details Compositions of β-glucans and specific antibodies Compositions of β-glucans and specific antibodies

2006-04-18

2006-04-18

Wilson, James O. (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S075000, C536S123100, C536S023100, C536S023200, C536S124000, C536S023700, C536S023500, C536S023600, C536S055100, C536S024300, C424S193100, C424S130100, C424S165100, C424S169100, C435S209000, C435S004000, C435S015000, C435S069100, C435S007320, C510S392000, C800S284000

Reexamination Certificate

active

07030101

ABSTRACT:
Compositions and kits comprising combinations of β-glucans and specific immunoglobulins are disclosed. The compositions and kits are useful in methods of preventing or treating infection by a pathogenic microorganism, in which β-glucan is administered to a subject, and specific antibodies to a pathogenic microorganism are introduced into the subject.

REFERENCES:
patent: 4739046 (1988-04-01), Di Luzio
patent: 4818752 (1989-04-01), Williams et al.
patent: 4833131 (1989-05-01), Williams et al.
patent: 4900722 (1990-02-01), Williams et al.
patent: 5032401 (1991-07-01), Jamas et al.
patent: 5401727 (1995-03-01), Rorstad et al.
patent: 5607677 (1997-03-01), Jamas et al.
patent: 5741495 (1998-04-01), Jamas et al.
patent: 5770208 (1998-06-01), Fattom et al.
patent: 5785975 (1998-07-01), Parikh
patent: 5961975 (1999-10-01), Fattom et al.
patent: 5965374 (1999-10-01), Herbstritt et al.
patent: 6194161 (2001-02-01), Fattom et al.
patent: 6355625 (2002-03-01), Pavliak et al.
patent: 96/14873 (1996-05-01), None
Penna et al.; “Pulmonary Metastases Neutralization and Tumor Rejection by In Vivo Administration of β Glucan and Bispecific Antibody”; Int. Journal Cancer; vol. 65; 1996; pp. 377-382.
Thibault et al.; “Tumor-infiltrating Lymphocytes can be ActivatedIn SituBy UsingIn VivoActivants Plus F(ab')2 Bispecific Antibodies”; Int. Journal Cancer; vol. 67; 1996; pp. 232-237.
Figueras; “Influence of the Sequence of Administration of β-Glucans and aVibrio damselaVaccine on the Immune Response of Turbot (Scophthalmus MaximusL.)”; Veterinary Immunology and Immunopathology; vol. 64; 1998; pp. 59-68.
Wakshull et al.; “PGG-Glucan, a Soluble β-(1,3)-glucan, Enhances the Oxidative Burst Response, Microbicidal Activity, and Activates an NF-kB-like Factor in Human PMN: Evidence for a Glycosphingolipid β-(1,3)-glucan Receptor”; Immunopharmacology; vol. 41; 1999; pp. 89-107.
Kossaczka et al., “Synthesis and immunological properties of Vi and Di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker”,Infect. Immun., 65(6):2088-2093.
Ostroff et al., “A new beta-glucan based macrophage-targeted adjuvant”,ACS Sumposium Ser. 469:52-59.

Affiliated with

Also associated with

Rating

Compositions of β-glucans and specific antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions of β-glucans and specific antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions of β-glucans and specific antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3567777